

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/790,268	03/01/2004	Leo J. Romanczyk JR.	1010/100US3	3127
32260 75	590 10/31/2005		EXAMINER	
NADA JAIN, P.C.		NUTTER, NATHAN M		
560 White Plair Tarrytown, NY	ns Road, Suite 460		ART UNIT	PAPER NUMBER
ranytown, 141	10371		1711	

DATE MAILED: 10/31/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

 $\begin{array}{l} \textbf{U.S. Patent and Trademark Office} \\ \textbf{Address: COMMISSIONER FOR PATENTS} \end{array}$

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
		·		EXAMINER
			ART UNIT	PAPER
				1005
			DATE MAILED	·):

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Nathan M. Nutter Primary Examiner Art Unit: 1711

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/790,268	ROMANCZYK ET AL.		
Examiner	Art Unit		
Nathan M. Nutter	1711		

_	The MAILING DATE of this communication appears on the cover sheet with the correspondence address
ГНЕ	REPLY FILED 21 October 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
	The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:
a)	The period for reply expires FOUR months from the mailing date of the final rejection.
b)	The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO
	MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
eer CFR abov earn	ensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have in filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 of 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) we, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any led patent term adjustment. See 37 CFR 1.704(b). TICE OF APPEAL
	The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date
	of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). ENDMENTS
_	
3. L	The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);
	(a) ☐ They raise the issue of new matter (see NOTE below);
	(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for
	appeal; and/or
	(d) They present additional claims without canceling a corresponding number of finally rejected claims.
	NOTE: (See 37 CFR 1.116 and 41.33(a)).
4 Г	The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
	Applicant's reply has overcome the following rejection(s):
3. F	Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling
J. L	the non-allowable claim(s).
7. [
	Claim(s) allowed:
	Claim(s) objected to:
	Claim(s) rejected:
	Claim(s) withdrawn from consideration:
	FIDAVIT OR OTHER EVIDENCE
в. [The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will <u>not</u> be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
9. [The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a
	showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
	☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.
	QUEST FOR RECONSIDERATION/OTHER
11.	The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
	Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). Other:
	Nathan M. Nutter Primary Examiner Art Unit: 1711

Continuation of 11. does NOT place the application in condition for allowance because: The reference to Tempesta teaches the pharmaceutical use at the paragraph bridging column 1 to column 2. The reference shows the use of proanthocyanidins, which admittedly embraces the compounds disclosed and claimed herein. Further, no Terminal disclaimer has been filed to overcome the rejection made under the judicially created doctrine of obviousness-type double patenting.